CHAPTER 7

Immunogenicity

Therapeutic proteins (biologics and biosimilars) may be recognised by the human immune system as antigens and could provoke an immune response, a process known as immunogenicity. Protein drug immunogenicity can lead to safety issues and impact drug efficacy and potency. Immunogenicity is defined as the propensity of antigenic motifs within therapeutic biologics to stimulate an immune response to itself and to related proteins or to induce immunologically related non-clinical effects or adverse events.

An immunogenic response to a biopharmaceutical is not necessarily undesirable; however, immunogenicity may in some cases lead to lack of efficacy and other unwanted effects. In this chapter, immunogenicity will refer to an adverse immune response to biologic drugs.

In this chapter, we discuss immune responses, factors affecting immunogenicity of therapeutic proteins, and the clinical practice guidance surrounding this.

Please wait while flipbook is loading. For more related info, FAQs and issues please refer to DearFlip WordPress Flipbook Plugin Help documentation.

Share content

Other learning chapters

Pharmacovigilance

Chapter 8

Pharmacovigilance

Evaluating why pharmacovigilance is essential to characterise the safety and efficacy of biopharmaceuticals and biosimilars
View chapter
Biosimilars in practice

Chapter 9

Biosimilars in practice

Detailing what to consider when reviewing a biosimilar for inclusion in a formulary and the role of pharmacists in implementing biosimilars into the health service
View chapter
Patient considerations and communication

chapter 10

Patient considerations and communication

Discussing the educational needs of patients about biosimilars and the pharmacists’ role in delivering advice and support to patients taking biosimilars
View chapter